^
Association details:
| Biomarker: | MGMT promoter methylation |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | temozolomide (DNA synthesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and association with MGMT (ECOG-ACRIN E2211)
Published date:
05/26/2022
Excerpt:
MGMT deficiency, defined as either low IHC or positive promoter methylation, was associated with greater odds of response (OR [95% CI] = 6.38 [2.19, 18.60] and 9.79 [1.09, 87.71], respectively). E2211 is the first prospective randomized trial of capecitabine/temozolomide and shows the longest PFS and highest RR reported for patients with pancreatic NETs in a prospective randomized study. MGMT deficiency was associated with greater odds of objective response.
Secondary therapy:
capecitabine
DOI:
10.1200/JCO.2022.40.16_suppl.4004
Trial ID:
Title:
The role of MGMT promoter methylation as a predictive factor for temozolomide-based treatment in neuroendocrine neoplasms: a prospective observational study.
Published date:
03/18/2022
Excerpt:
The aim of this study was to prospectively evaluate the role of MGMT status in predicting response to TEM-based treatment in NET patients….In the MGMT-methylated population, median PFS was 34 months [IQR:15-58], compared to 14 [IQR:8-38] in non-methylated patients. MGMT-promoter methylation status was the only independent variable related to PFS....This study has prospectively demonstrated the role of MGMT-promoter methylation status as good predictive factor for TEM-based treatment in NET patients.
DOI:
10.48676/unibo/amsdottorato/10068
